263 related articles for article (PubMed ID: 16823087)
1. Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment.
Yedjou CG; Moore P; Tchounwou PB
Int J Environ Res Public Health; 2006 Jun; 3(2):136-40. PubMed ID: 16823087
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
3. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.
Yedjou C; Tchounwou P; Jenkins J; McMurray R
J Hematol Oncol; 2010 Aug; 3():28. PubMed ID: 20796291
[TBL] [Abstract][Full Text] [Related]
4. Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide.
Chen J; Cheng J; Yi J; Xie B; Lin L; Liu Z; Zhao H; Wang B; Ai Z; Yang Y; Wei H
Leuk Res; 2016 Nov; 50():116-122. PubMed ID: 27736728
[TBL] [Abstract][Full Text] [Related]
5. Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Peng CY; Jiang J; Zheng HT; Liu XS
Leuk Lymphoma; 2010 Feb; 51(2):297-303. PubMed ID: 20038232
[TBL] [Abstract][Full Text] [Related]
6. Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells.
Mirjalili S; Khaleghian A; Kalalinia F
Biometals; 2021 Oct; 34(5):1067-1080. PubMed ID: 34255251
[TBL] [Abstract][Full Text] [Related]
7. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
8. Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Ye Y; Xu X; Zhang M; Qiu D; Bai X; Wang J; Weng G; Zhou R; Guo Z; He H; Yi W; He X; Guo K
Leuk Lymphoma; 2015; 56(11):3159-67. PubMed ID: 25739941
[TBL] [Abstract][Full Text] [Related]
9. [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai YX; Meng FY; Sun QX; Fu YB; Li L
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):737-40. PubMed ID: 19176009
[TBL] [Abstract][Full Text] [Related]
10. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
11. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
Lu M; Levin J; Sulpice E; Sequeira-Le Grand A; Alemany M; Caen JP; Han ZC
Exp Hematol; 1999 May; 27(5):845-52. PubMed ID: 10340400
[TBL] [Abstract][Full Text] [Related]
12. Arsenic-induced apoptosis in malignant cells in vitro.
Akao Y; Yamada H; Nakagawa Y
Leuk Lymphoma; 2000 Mar; 37(1-2):53-63. PubMed ID: 10721769
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
Kumar S; Yedjou CG; Tchounwou PB
J Exp Clin Cancer Res; 2014 May; 33(1):42. PubMed ID: 24887205
[TBL] [Abstract][Full Text] [Related]
14. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Calleja EM; Warrell RP
Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887
[TBL] [Abstract][Full Text] [Related]
15. In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays.
Yedjou CG; Tchounwou PB
Mol Cell Biochem; 2007 Jul; 301(1-2):123-30. PubMed ID: 17216127
[TBL] [Abstract][Full Text] [Related]
16. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
17. Combination Effect of Deferoxamine and Arsenic Trioxide on Viability and Vitality of APL Like Cell Line.
Ghaffari K; Bayat A; Ghasemi A
Ethiop J Health Sci; 2023 Jul; 33(4):703-710. PubMed ID: 38784214
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.
Yuksel S; Saydam G; Uslu R; Sanli UA; Terzioglu E; Buyukececi F; Omay SB
Leuk Res; 2002 Apr; 26(4):391-8. PubMed ID: 11839383
[TBL] [Abstract][Full Text] [Related]
20. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Bashash D; Ghaffari SH; Zaker F; Kazerani M; Hezave K; Hassani S; Rostami M; Alimoghaddam K; Ghavamzadeh A
Anticancer Agents Med Chem; 2013 Sep; 13(7):1115-25. PubMed ID: 23293885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
